ABDALLAH DLEWATI
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism FLINT, MI NPI 1609054899
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism MI Lilly USA, LLC All categories
General Payments — all program years on this page
$9,039.76
- Category: General Payments
- Program years: PY2018–2024
- Record count: 514
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,490.08 across 72 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,490.08 | 72 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $233.82 | 11 |
| Novo Nordisk AS | $118.88 | 6 |
| Amgen Inc. | $117.85 | 5 |
| SANOFI-AVENTIS U.S. LLC | $90.23 | 4 |
| Abbott Laboratories | $78.95 | 4 |
| Astellas Pharma US Inc | $77.50 | 4 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $70.81 | 3 |
| ABBVIE INC. | $70.34 | 4 |
| Antares Pharma, Inc. | $46.33 | 2 |
| Alexion Pharmaceuticals, Inc. | $45.77 | 2 |
| Corcept Therapeutics | $43.55 | 2 |
| Esperion Therapeutics, Inc. | $43.25 | 2 |
| Radius Health, Inc. | $42.73 | 2 |
| Alvogen Inc | $39.23 | 2 |
| Insulet Corporation | $38.30 | 2 |
| PFIZER INC. | $36.29 | 2 |
| BETA BIONICS, INC. | $27.78 | 1 |
| EVOKE PHARMA, INC. | $22.70 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $22.64 | 1 |
| Ascensia Diabetes Care US Inc. | $21.42 | 1 |
| Amphastar Pharmaceuticals, Inc. | $21.38 | 1 |
| Amneal Pharmaceuticals LLC | $21.05 | 1 |
| Xeris Pharmaceuticals, Inc. | $20.89 | 1 |
| Verity Pharmaceuticals Inc. | $20.49 | 1 |
| Kyowa Kirin, Inc. | $19.94 | 1 |
| DEXCOM, INC. | $19.54 | 1 |
| RECORDATI_RARE_DISEASES_INC. | $18.63 | 1 |
| Acella Pharmaceuticals, LLC | $16.86 | 1 |
| CeQur Corporation | $16.12 | 1 |
| Medtronic, Inc. | $15.97 | 1 |
| TheracosBio, LLC | $10.84 | 1 |
By program year
Records — PY2024 (72)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.